Cargando…

Integrated multi-omics characterization of KRAS mutant colorectal cancer

KRAS mutation is the most frequent oncogenic aberration in colorectal cancer (CRC). The molecular mechanism and clinical implications of KRAS mutation in CRC remain unclear and show high heterogeneity within these tumors. Methods: We harnessed the multi-omics data (genomic, transcriptomic, proteomic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chong, Wei, Zhu, Xingyu, Ren, Huicheng, Ye, Chunshui, Xu, Kang, Wang, Zhe, Jia, Shengtao, Shang, Liang, Li, Leping, Chen, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274732/ https://www.ncbi.nlm.nih.gov/pubmed/35836817 http://dx.doi.org/10.7150/thno.73089

Ejemplares similares

ITGB1-mediated molecular landscape and cuproptosis phenotype induced the worse prognosis in diffuse gastric cancer
por: Zhu, Xingyu, et al.
Publicado: (2023)

A narrative review of intraoperative use of indocyanine green fluorescence imaging in gastrointestinal cancer: situation and future directions
por: Li, Han, et al.
Publicado: (2023)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis
por: Kundu, Snehangshu, et al.
Publicado: (2021)

Omics and Multi-Omics in IBD: No Integration, No Breakthroughs
por: Fiocchi, Claudio
Publicado: (2023)

Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
por: Knickelbein, Kyle, et al.
Publicado: (2014)

Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosis
por: Park, Sujeong, et al.
Publicado: (2018)

Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
por: Zhong, Longhui, et al.
Publicado: (2020)

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
por: Ruan, Hang, et al.
Publicado: (2022)

Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
por: Zhou, Qiming, et al.
Publicado: (2023)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Oleic acid-induced metastasis of KRAS/p53-mutant colorectal cancer relies on concurrent KRAS activation and IL-8 expression bypassing EGFR activation
por: Shen, Chih-Jie, et al.
Publicado: (2023)

Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients
por: Liu, Jungang, et al.
Publicado: (2021)

Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer
por: Hiraki, Masayuki, et al.
Publicado: (2015)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy
por: Alves, Sara, et al.
Publicado: (2015)

MICA (∗)012:01 Allele Facilitates the Metastasis of KRAS-Mutant Colorectal Cancer
por: Ding, Weifeng, et al.
Publicado: (2020)

Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer
por: Liu, Huashan, et al.
Publicado: (2021)

A Review of Integrative Imputation for Multi-Omics Datasets
por: Song, Meng, et al.
Publicado: (2020)

Effect of KRAS mutations and p53 expression on the postoperative prognosis of patients with colorectal cancer
por: Wang, Lingfeng, et al.
Publicado: (2022)

MinOmics, an Integrative and Immersive Tool for Multi-Omics Analysis
por: Maes, Alexandre, et al.
Publicado: (2018)

Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures
por: Aldana, Julian, et al.
Publicado: (2023)

Dietary spinach reshapes the gut microbiome in an Apc-mutant genetic background: mechanistic insights from integrated multi-omics
por: Chen, Ying-Shiuan, et al.
Publicado: (2021)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Machine learning for multi-omics data integration in cancer
por: Cai, Zhaoxiang, et al.
Publicado: (2022)

Editorial: Multi-omic data integration
por: Nardini, Christine, et al.
Publicado: (2015)

Integrative Multi-Omics in Biomedical Research
por: Hill, Michelle M., et al.
Publicado: (2021)

Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells
por: Cheon, Seul‐Ki, et al.
Publicado: (2018)

Rab13 regulates sEV secretion in mutant KRAS colorectal cancer cells
por: Hinger, Scott A., et al.
Publicado: (2020)

Targeting oxidative pentose phosphate pathway prevents recurrence in mutant Kras colorectal carcinomas
por: Gao, WenChao, et al.
Publicado: (2019)

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer
por: Wang, Haiyun, et al.
Publicado: (2019)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients
por: Naseem, Madiha, et al.
Publicado: (2021)

The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer
por: Wong, Chi Chun, et al.
Publicado: (2022)

GraphOmics: an interactive platform to explore and integrate multi-omics data
por: Wandy, Joe, et al.
Publicado: (2021)

Integrative multi‐omic analysis reveals neurodevelopmental gene dysregulation in CIC ‐knockout and IDH1 ‐mutant cells
por: Lee, Stephen D, et al.
Publicado: (2021)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pf1ura8hg7sgljnb3j12gp62pu